Many Chinese pharmaceutical and biotech companies are demonstrating results from their new anti-cancer drug development in the global market. Companies like Jiangsu Hengrui Pharmaceuticals and BeiGene have obtained approvals for their immunotherapy and targeted anti-cancer agents from the regulatory authorities globally, including South Korea, the United States, and Europe.

The gap between Chinese and Korean pharmaceutical and biotech companies has increased as Chinese companies succeeded in commercialization and Phase 3 clinical trial entries. It has been reported that most new anti-cancer drugs from Korean pharmaceutical and biotech companies remain in the preclinical stages or phase 1 clinical trials.